Trial Profile
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Casimersen (Primary) ; Golodirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- Acronyms ESSENCE
- Sponsors Sarepta Therapeutics
- 16 Feb 2023 Planned End Date changed from 30 Apr 2024 to 3 Oct 2025.
- 16 Feb 2023 Planned primary completion date changed from 30 Apr 2024 to 3 Oct 2025.
- 17 Jan 2023 Status changed from recruiting to active, no longer recruiting.